Your session is about to expire
← Back to Search
Escape for Smoking
N/A
Waitlist Available
Led By Mary E. Cooley, PhD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing the ESCAPE program to see if it can help women with HIV quit smoking and improve their lung health.
Who is the study for?
This trial is for high-risk smokers aged 55-77 who smoke at least 5 cigarettes a day and have a history of heavy smoking (≥30 pack years). Participants must be English-speaking, own a mobile phone with video call capability, have active health insurance, and can complete an interview. They should not have had lung cancer or low-dose CT screening before.
What is being tested?
The study compares the ESCAPE program—a smoking cessation approach that includes education on lung screening—to standard care. The goal is to see if adding lung screening information helps people quit smoking more effectively and improves their overall lung health.
What are the potential side effects?
Since this trial focuses on behavioral intervention rather than medication, traditional side effects are not expected. However, participants may experience stress or anxiety related to quitting smoking or from changes in behavior due to the program.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
7-day point prevalence smoking cessation rate
Malignant Neoplasms
number of cigarettes smoked/day
Secondary study objectives
Completion rate
Narrative Engagement Scale scores
Percentage of the group indicate that the film would have value to others
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Standard CareExperimental Treatment1 Intervention
The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
Group II: EscapeExperimental Treatment1 Intervention
The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening
Find a Location
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,110 Previous Clinical Trials
358,145 Total Patients Enrolled
American Association for Cancer ResearchOTHER
8 Previous Clinical Trials
679 Total Patients Enrolled
Mary E. Cooley, PhDPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
1 Previous Clinical Trials
179 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am unable to give consent for medical procedures.I am between 55 and 77 years old.I am under 18 years old.I can participate in an interview.I can do most of my daily activities without help.I have never had lung cancer before.
Research Study Groups:
This trial has the following groups:- Group 1: Standard Care
- Group 2: Escape
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.